Projekt

CONVERT-AF

Abgebrochen · 2013 bis 2017

Art
Klinische Forschung
Reichweite
Multizentrisch, KSSG als teilnehmendes Zentrum
Bereiche
Status
Abgebrochen
Start
2013
Ende
2017
Finanzierungsart
Industrie
Studiendesign
Double blind, placebo-controlled randomized trial
Projektpartner
Universitätsspital Basel
Kurzbeschreibung/Zielsetzung

Canakinumab for the prevention of recurrences after electrical cardioversion in patients with persistent atrial fibrillation
(CONVERT-AF) trial

Primary objective:
To determine the effect of canakinumab on atrial fibrillation (AF) recurrences within 6 months after electrical cardioversion in patients with persistent AF

Secondary objectives:
To determine the effect of canakinumab on
- Recurrences of documented AF within 1 month after cardioversion
- Recurrences of documented AF within 3 months after cardioversion
- Time to first redo cardioversion
- Use of antiarrhythmic drugs (Vaughan Williams class 1 or 3) at 6 m
- Survival free of unplanned hospitalizations
- Change in CRP levels from randomization to 6 months